Key(tone) Takes From ADA: Libre Duo 2H26 OUS & US Launch; New ABT Ketone Data

Research evidence excerpt

Key(tone) Takes From ADA: Libre Duo 2H26 OUS & US Launch; New ABT Ketone Data

USA | Medical Supplies & Devices

Abbott EquityJuneResearch7, 2026

FLASH NOTEKey(tone) Takes From ADA: Libre Duo 2H26 OUS

RATING BUY& US Launch; New ABT Ketone Data

PRICE $91.07^

ABT showcased Libre Assist App and Libre Duo at ADA 2026. Key takes: 1)

Libre Assist uses AI for real-time meal guidance, available now, deepening T2D PRICE TARGET | % TO PT $135.00 | +48%

engagement; 2) Libre Duo addresses rising DKA risk, CE Mark in hand, US launch 52W HIGH-LOW $139.06 - $81.97

2H26; 3) New DKA data released from ABT inc data showing 10% of DKA events FLOAT (%) | ADV MM (USD) 99.0% | 1,148.13

occur without elevated glucose 4) ADA issued new glucose-ketone guidelines & MARKET CAP $159.1B

new decision algos; 5) ABT in talks with pump cos on CKM-AID algo integration. TICKER ABT ^Prior trading day's closing price unless otherwise

noted.

At ADA, ABT showcased the Libre Assist app and the Dual Glucose-Ketone sensor (Libre

Duo). Libre Assist leverages AI to provide real-time, personalized mealtime guidance by allowing

users to photograph their meal within the Libre app, with the AI identifying food components and

offering actionable suggestions (portion adjustments, eating order, hydration) to minimize glycemic

response. When paired with a Libre sensor, the system creates a closed feedback loop that tracks

post-meal glucose responses, with plans to eventually enable personalized learning over time and

targeting improved time-in-range by consistently optimizing a patient's worst meals of the day. The

app is currently available for download, positioning ABT to deepen engagement with T2D pts.

ABT's Libre Duo is first-to-market in CKM, integrating continuous ketone monitoring with CGM